Veeral Sheth, MD
Ophthalmology · Oak Forest, ILNPI 1881806784
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Genentech USA, Inc. at 31.4% of the total. Among ophthalmology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 494 payments — averaging $1449.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$225K
- F. Hoffmann-la Roche AG$161K
- Astellas Pharma US Inc$95K
- Alimera Sciences, Inc.$69K
- Apellis Pharmaceuticals, Inc.$47K
- Novartis$43K
- plus $75K from 24 others
Across 2,656 payments — averaging $5329.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$8.1M
- Regeneron$2.9M
- Novartis$871K
- Ocular Therapeutix, Inc.$621K
- Hexal AG$369K
- Bayer$288K
- plus $1M from 12 others
What the payments were for
- Consulting fees$366,42651%
- Speaking & faculty fees$264,91737%
- Travel & lodging$69,26210%
- Food & beverage$14,7412%
- Education$5830%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 120 | $224,807 |
| F. Hoffmann-la Roche AG | 65 | $161,208 |
| Astellas Pharma US Inc | 32 | $94,992 |
| Alimera Sciences, Inc. | 60 | $69,416 |
| Apellis Pharmaceuticals, Inc. | 42 | $47,159 |
| Novartis | 37 | $43,242 |
| Regeneron Healthcare Solutions, Inc. | 42 | $21,964 |
| Regeneron | 12 | $13,528 |
| Genentech, Inc. | 10 | $12,637 |
| Eyepoint US, Inc. | 15 | $7,274 |
| Astellas Pharma Global Development | 2 | $3,833 |
| Ocular Therapeutix, Inc. | 7 | $3,291 |
| Neurotech Pharmaceuticals, Inc. | 1 | $3,155 |
| Roche Products Limited | 1 | $2,224 |
| ANI Pharmaceuticals, Inc. | 2 | $2,039 |
| Boehringer Ingelheim International GmbH | 2 | $1,900 |
| Notal Vision, Inc. | 1 | $1,300 |
| AbbVie(2 entities) | 20 | $660 |
| Alcon | 3 | $439 |
| Harrow Eye, LLC | 3 | $387 |
| Johnson & Johnson | 1 | $109 |
| Mallinckrodt Hospital Products Inc. | 4 | $76 |
| Coherus Oncology, Inc. | 2 | $61 |
| Bausch & Lomb Americas Inc. | 2 | $53 |
| Astellas Pharma Europe Ltd | 1 | $52 |
| Integra Lifesciences Corporation | 2 | $36 |
| Carl Zeiss Meditec, Inc. | 2 | $30 |
| Biogen | 1 | $26 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $17 |
| Mallinckrodt Enterprises LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VABYSMO$138,109
- Izervay$90,410
- Lucentis$76,228
- Iluvien$70,123
- SUSVIMO$57,956
- EYLEA$21,917
- BEOVU$18,517
- Syfovre$17,752
- EYLEA HD$12,573
- Non-Covered Product$10,012
- EYP-1901$5,349
- YUTIQ$1,868
- ForeseeHome$1,300
- IHEEZO$314
- Constellation$292
- DEXTENZA$174
- NGENUITY$146
- XIIDRA$124
- BUPARLISIB$122
- Teligen$109
How this compares
$715,928 in reported general payments places this provider in the 95th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Brimonidine Tartrate | 28 | $2,289 |
| Prednisolone Acetate | 45 | $1,375 |
| Latanoprost | 98 | $1,287 |
| Ketorolac Tromethamine | 72 | $1,269 |
| MoxifloxacinMoxifloxacin Hcl | 28 | $593 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 25 | $553 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Oak Forest
- Rama JagerOak Forest$227K
- Harit BhattOak Forest$78K
- Meena GeorgeOak Forest$28K
- Seenu HariprasadChicago$2.3M
- Lisa NijmSpringfield$1.7M
- Kathleen MornoNorth Riverside$1.2M
- James KatzDes Plaines$642K
- Mitchell JacksonLake Villa$584K
- David LubeckHomewood$575K
- Parag MajmudarHighland Park$451K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.